Meiji Yasuda Life Insurance Co Has $1.09 Million Stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Share on StockTwits

Meiji Yasuda Life Insurance Co decreased its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.3% in the 1st quarter, HoldingsChannel.com reports. The fund owned 8,065 shares of the biopharmaceutical company’s stock after selling 455 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in Alexion Pharmaceuticals were worth $1,090,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Investors Research Corp acquired a new stake in Alexion Pharmaceuticals in the first quarter worth about $27,000. Captrust Financial Advisors acquired a new stake in Alexion Pharmaceuticals in the fourth quarter worth about $31,000. Berman Capital Advisors LLC lifted its holdings in Alexion Pharmaceuticals by 68.6% in the first quarter. Berman Capital Advisors LLC now owns 322 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 131 shares during the period. Institutional & Family Asset Management LLC lifted its holdings in Alexion Pharmaceuticals by 39.5% in the first quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 87 shares during the period. Finally, Kaizen Advisory LLC lifted its holdings in Alexion Pharmaceuticals by 22.2% in the fourth quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 111 shares during the period. 94.51% of the stock is owned by institutional investors.

Several equities research analysts have commented on ALXN shares. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Raymond James boosted their price target on shares of Alexion Pharmaceuticals from $161.00 to $164.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 17th. Goldman Sachs Group reiterated a “neutral” rating and issued a $142.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, May 23rd. Finally, Guggenheim reiterated a “neutral” rating and issued a $135.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $161.06.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker sold 300,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $123.74, for a total transaction of $37,122,000.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.08% of the stock is currently owned by insiders.

NASDAQ ALXN traded up $3.53 on Wednesday, hitting $120.67. 51,775 shares of the company were exchanged, compared to its average volume of 1,507,136. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. The company has a market cap of $26.27 billion, a PE ratio of 16.98, a PEG ratio of 0.93 and a beta of 1.58. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.68 EPS. Research analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.61 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Meiji Yasuda Life Insurance Co Has $1.09 Million Stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://weekherald.com/2019/06/12/meiji-yasuda-life-insurance-co-has-1-09-million-stake-in-alexion-pharmaceuticals-inc-nasdaqalxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: What are economic reports?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.